New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its ... (wide. In the U.S. REMICADE is approv...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> TECHNOLOGY

New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study

Date:10/6/2008

wide.
In the U.S., REMICADE is approved for the following indications:

-- Reducing signs and symptoms, inhibiting the progression of structural

damage and improving physical function in patients with moderately to

severely active RA, when administered in combination with methotrexate.

-- Reducing signs and symptoms in patients with active AS.

-- Reducing signs and symptoms and inducing and maintaining clinical

remission in adult and pediatric patients with moderately to severely

active CD who have had an inadequate response to conventional therapy.

-- Reducing the number of draining enterocutaneous and rectovaginal

fistulas and maintaining fistula closure in adult patients with

fistulizing CD.

-- Reducing signs and symptoms, inducing and maintaining clinical

remission and mucosal healing, and eliminating corticosteroid use in

patients with moderately to severely active UC who have had an

inadequate response to conventional therapy.

-- Reducing signs and symptoms of active arthritis, inhibiting the

progression of structural damage and improving physical function in

patients with PsA.

-- Treatment of adult patients with chronic severe plaque PsO who are

candidates for systemic therapy and when other systemic therapies are

medically less appropriate.

REMICADE is unique among available anti-TNF biologic therapies. Unlike self-administered therapies that require patients to inject themselves frequently, REMICADE is the only anti-TNF biologic administered directly by caregivers in the clinic or office setting. REMICADE is a two-hour infusion administered every 6 or 8 weeks (indication-dependent), following a standard induction regimen that requires treatment at weeks 0, 2 and 6. As a result, REMICADE patients may require as few as six treatments each year.

Important Safety Information

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. More Findings on Gene Involved in Childhood Asthma
2. Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis
3. VAI Findings Could Aid Diagnosis and Treatment of Several Types of Kidney Cancer
4. Findings on Bladder-Brain Link May Point to Better Treatments for Problems in Sleep, Attention
5. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
6. FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years
7. Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
8. Study Findings Show Infection Control Intervention Helps Keep Kids in School
9. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
10. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
11. ACORN Presents Findings of Collaborative Metastatic Colorectal Cancer Research

Post Your Comments:

(Date:5/17/2013)... , May 17, 2013 Atossa Genetics, Inc. (NASDAQ: ... Kyle Guse , Chief Financial Officer & ... MicroCap Conference on Thursday, May 30, 2013, in ... The Company,s presentation is scheduled to begin ... live webcast. To access the webcast, go to www.atossagenetics.com ...

(Date:5/16/2013)... and ZURICH , May 17, 2013 /PRNewswire/ ... Science, Technology and Research (A*STAR) and Switzerland,s ... volunteer has been dosed in a Phase 1 clinical trial ... bacteriophage Qbeta virus-like particle (VLP) technology. In this first Phase ... vaccine candidate and its potential to protect against H1N1 influenza ...

(Date:5/16/2013)... SYDNEY , May 16, 2013 HeartWare ... a leading innovator of less invasive, miniaturized circulatory support technologies ... announced that CEO Doug Godshall is ... at 11:00 a.m. EDT on Monday, May 20, 2013. The ... New York Hotel. A live webcast of the ...

Breaking Medicine Technology:Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 2 Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 3 A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2 A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3 A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4 A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5 A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6 HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast 2

[0] Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference [0] A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing [0] HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast

... ... ... ... ...

... ... ... , ... , , , ...

Cached Medicine Technology:Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy is More Potent Than Double Combinations or Monotherapy Against Drug-Resistant Flu Strains 2 Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy is More Potent Than Double Combinations or Monotherapy Against Drug-Resistant Flu Strains 3 Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy is More Potent Than Double Combinations or Monotherapy Against Drug-Resistant Flu Strains 4 Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy is More Potent Than Double Combinations or Monotherapy Against Drug-Resistant Flu Strains 5 Ritter Pharmaceuticals Joins NIH Conference Discussions on Lactose Intolerance and Associated Health Risks 2 Ritter Pharmaceuticals Joins NIH Conference Discussions on Lactose Intolerance and Associated Health Risks 3

Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy is More Potent Than Double Combinations or Monotherapy Against Drug-Resistant Flu Strains Ritter Pharmaceuticals Joins NIH Conference Discussions on Lactose Intolerance and Associated Health Risks

(Date:5/19/2013)... Buenos Aires, Argentina: Yoga classes ( clases de Yoga ... by the Sivananda Yoga Vedanta Center. The center ... Norte). Classes are 90 minutes and are offered all ... a calm environment, allowing visitors to enjoy the benefits ... among others. , The Yoga classes follow the following ...

(Date:5/19/2013)... (PRWEB) May 19, 2013 The legal ... website YazSideEffects.com in a concerted effort to connect women ... combination birth control drugs Yaz, Yasmin & Ocella with ... wealth of information on the notorious birth control drugs ... Bayer Pharmaceuticals. , Yaz, Yasmin & Ocella were ...

(Date:5/18/2013)... (PRWEB) May 18, 2013 Daily Gossip issued ... a new review on their page. John Colston, Daily Gossip’s ... to Shaun Hadsall’s revolutionizing 14-Day Rapid Fat Loss Plan ... sustain that carbs are healthy at a time when nutritionists ... from highly caloric products. , The diet is based ...

(Date:5/18/2013)... May 18, 2013 Also known as ... increasingly popular weight loss surgery that guarantees patients long-term ... Center wishes to give readers a brief tutorial ... attended medical school at New York City’s Mount Sinai ... Methodist he undertook a fellowship in Minimally Invasive Bariatric ...

(Date:5/18/2013)... May 18 (HealthDay News) -- Children who swallow high-powered ... remove the objects, according to a new study. ... in New Orleans, found that more than 79 percent ... either surgery or an endoscopic procedure, in which a ... tract. Only 21 percent of these cases can be ...

Breaking Medicine News(10 mins):Health News:Clases de Yoga in Buenos Aires, Argentina (Yoga Classes) Now Offered by Sivananda Yoga Vedanta Center 2 Health News:Yazsideeffects.com Connects Yaz Side Effects Sufferers With Yaz Side Effects Lawyers 2 Health News:Everything You Need to Know About Lap Band Surgery 2 Health News:Everything You Need to Know About Lap Band Surgery 3 Health News:Swallowing Magnets Can Be Fatal for Children 2

[0] Clases de Yoga in Buenos Aires, Argentina (Yoga Classes) Now Offered by Sivananda Yoga Vedanta Center [0] Yazsideeffects.com Connects Yaz Side Effects Sufferers With Yaz Side Effects Lawyers [0] 14 Day Rapid Fat Loss Plan Review of Shaun Hadsall's Diet and Workout Secrets Revealed By Daily Gossip [0] Everything You Need to Know About Lap Band Surgery [0] Swallowing Magnets Can Be Fatal for Children

... , , WOONSOCKET, R.I., ... not take their medications, but being busy or simply forgetting top the ... ten consumers (28%) sometimes forget to refill their prescriptions on time, and ... to a daily medication schedule. In addition, more than half (52%) ...

... , , , ... 13 As Americans are becoming increasingly aware of probiotics, ... and Prebiotics (ISAPP) provide increased clarity about the definition of ... percent) of Americans said they are aware of the term ...

... R.I., Aug. 13 CVS Caremark (NYSE: CVS ... examined consumer attitudes and behaviors around health care and prescription usage. ... coverage along with cost savings realized by improving health care delivery. , ... E75914LOGO ) , , Of all consumers ...

... , , , ... American Veterinary Medical Association (AVMA) is unveiling a new online pre ... multiple improvements to the tools and resources available to journalists. , , ... covering the complex and often controversial issues in veterinary medicine as easy as ...

... , ALLEGAN, Mich., Aug. 13 Perrigo ... its Board of Directors declared a quarterly dividend of $0.055 ... record on August 28, 2009. , , ... that develops, manufactures and distributes over-the-counter (OTC) and generic prescription ...

... Israel, Aug. 13 Shamir Optical Industry Ltd. (Nasdaq: ... and technology to the ophthalmic lens market, today announced unaudited financial ... , For the quarter ended June 30, 2009, revenues ... same period in 2008. The decrease in revenues was mainly due ...

CVS/pharmacy Helping Consumers with Challenge of Filling Prescriptions on Time New Guidelines Provide Clarity About Probiotics CVS Caremark Announces Results of 2009 Health IQ Study AVMA Unveils Improved Online Press Room to Help Journalists Perrigo Company Announces Quarterly Dividend Shamir Optical Industry Ltd. Reports Second Quarter 2009 Results

... readers offering 96-channel parallel detection of fluorescence, ... 1,536-well microtiter plates. Compact workstations and ... the transport of microtiter plates with a ... The need for mechanical switching required by ...

... 1495-051 96PW washes all 96 ... and automatically. Separate wash and ... and excellent washing ability. Pre-programmed ... easily removable 96-channel head reduce ...

... SkanWasher 300 with ... system. Vacuum pressure and ... heights are adjustable. On-board ... configure 8 different programs. ...

... Automatic 96-well microplate washer ... Vacuum pressure, air pressure, and ... are adjustable. On-board software for ... programs. External vacuum pump required. ...

Medicine Products:

The UHTS system from Carl Zeiss Jena 96PW Microplate Washer SkanStacker (110V)SkanWasher 300 (110V)